Exegenesis Bio is a rapidly growing global gene therapy company developing innovative genetic medicines for eye, central nervous system (CNS), and liver-directed diseases. Its core work centers on genetic medicines targeting ophthalmologic, CNS and hepatic disorders. In June 2021 the company completed a Series B++ financing, raising over $50M of venture investments in the round. That financing was led by Hillhouse Capital Group and included existing investors LYFE Capital and BioTrack Capital alongside new investors Temasek Holdings, CPE and Lake Bleu Capital. The company has raised $120M to date. Exegenesis is based in Philadelphia, PA. Exegenesis Bio develops gene therapies with a goal of providing safe, effective, one-time curative treatments that are affordable and accessible globally. The company works across viral vector design, preclinical and clinical development, and process development for large-scale manufacturing. It built a cGMP-compliant gene therapy production workshop meeting China, US and EU standards in four months and emphasizes a scalable, cost-controlled platform to accelerate multiple product lines to clinic. Founded in July 2019 and based in Hangzhou, Exegenesis is led by a founding team with extensive gene- and cell-therapy R&D and GMP manufacturing experience from U.S. companies. The firm has multiple gene-therapy pipelines in development and intends to use new capital to advance those programs through clinical and R&D stages. Exegenesis positions its integrated capabilities—from vector design to GMP production—as a competitive advantage for rapid clinical translation and commercialization.

Total raised

$50M

Funding rounds

2

Latest round

Series B

Latest activity

Jun 2021